Biohaven Bioscience Ireland

Company snapshot

Biohaven Bioscience Ireland is a pharma organization headquartered in GB. Primary therapeutic focus areas include Refractory Focal Onset Epilepsy, Early Parkinson’s Disease, Graves Disease, Pain, Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures. NovaPharmaNews links 7 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (3), phase 1 (2), phase 2 (2).

• 7 active pipeline program(s) linked via ClinicalTrials.gov.
• 7 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Biohaven Bioscience Ireland. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Biohaven Bioscience Ireland.

1. Jun 8, 2026 Clinical update

   BHV8000-301 — Phase 3

2. Jun 8, 2026 Clinical update

   BHV7000-304 — Phase 3

3. Jun 8, 2026 Clinical update

   BHV7000-303 — Phase 3

4. Jun 8, 2026 Clinical update

   BHV7000-302 — Phase 2

5. Jun 8, 2026 Clinical update

   BHV2100-112 — Phase 1

View all clinical trial activity →

• What is Biohaven Bioscience Ireland?

  Biohaven Bioscience Ireland is a pharma organization headquartered in GB. Primary therapeutic focus areas include Refractory Focal Onset Epilepsy, Early Parkinson’s Disease, Graves Disease, Pain, Idiopathic Generalized Epilepsy with Generalized Tonic-clonic Seizures. NovaPharmaNe

• Is Biohaven Bioscience Ireland publicly traded?

  Biohaven Bioscience Ireland appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Biohaven Bioscience Ireland develop or market?

  We link 8 drug profile(s) where Biohaven Bioscience Ireland is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/biohaven-bioscience-ireland-limited#company-drugs.

• What are the latest developments for Biohaven Bioscience Ireland?

  In the last 12 months our linked public records show 7 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Biohaven Bioscience Ireland focus on?

  Biohaven Bioscience Ireland focuses on Refractory Focal Onset Epilepsy, Early Parkinson’s Disease, Graves Disease based on our analysis of their pipeline programs and drug development activities.